We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HAEMONETICS

Haemonetics Corporation’s comprehensive portfolio of devices, information management, and consulting services offers ... read more Featured Products: More products

Download Mobile App




Coagulopathy Testing Linked to Better COVID-19 Outcomes

By LabMedica International staff writers
Posted on 19 Jan 2021
Print article
Image: The TEG 5000 Thrombelastograph Hemostasis Analyzer system is a diagnostic instrument that provides comprehensive whole blood hemostasis testing that can help assess bleeding and thrombotic risks, and also monitor antithrombotic therapies (Photo courtesy of Haemonetics).
Image: The TEG 5000 Thrombelastograph Hemostasis Analyzer system is a diagnostic instrument that provides comprehensive whole blood hemostasis testing that can help assess bleeding and thrombotic risks, and also monitor antithrombotic therapies (Photo courtesy of Haemonetics).
Significant infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to development of coagulopathy, most typically a hypercoagulable state. In addition to thrombotic conditions, coronavirus disease 2019 (COVID-19) patients may develop hemorrhagic complications, which have been under recognized or inadequately emphasized in prior studies.

Thromboelastography (TEG), being a whole blood assay, is a more inclusive technology that evaluates the overall contribution of blood cells, platelets, and plasma during clot formation by mimicking in vivo coagulation processes. TEG can measure profound hemostatic derangements, and it identifies key dysfunctional components, from the initiation phase of blood clotting to the fibrinolysis phase.

A multidisciplinary team working with the Memorial Regional Hospital (Hollywood, FL, USA) and the hospital-based Thromboelastography Task Force (TTF) prospectively followed 100 patients meeting certain criteria to assist with the application and interpretation of initial and on-going TEG findings over a five month period. Included in the TEG was platelet mapping (TEG-PM). Among the 100 patients studied, ages ranged from 32 to 91 years, and 67% were male, 46.5% African American, 29.3% Hispanic.

For identification of Coagulopathy Based on TEG-PM, the TTF used the processing device TEG 5000 Thrombelastograph Hemostasis Analyzer (Haemonetics, Boston, MA, USA), with PM employed to specifically assess activation of the platelet’s cyclooxygenase 1 (maximum amplitude [MA]-arachidonic acid [AA]) and P2Y12 pathways (MA-adenosine diphosphate [ADP]). Follow-up TEG-PM assays were clinician ordered and collected every 48–72 hours when possible.

The scientists reported that among 100 COVID-19 patients who got TEG-PM upon admission at a center where it was routine for hypoxemic patients in the emergency department, death was 7.7-fold more common among those whose treatment did not follow the TEG-guided treatment algorithm (17 of 28 [60.7%] versus four of 72 [5.6%]. Inflammatory markers were associated with clinical deterioration, pulmonary failure (PF), acute kidney injury (AKI), and death. D-dimer was significantly higher in non-Algorithm-Guided (AG) patients, but ferritin and C-reactive protein (CRP) were not significantly different between the two groups. For non-survivors, irreversible thrombocytopenia (< 100,000/µL) was an unmistakable sign of deterioration/death.

The authors concluded that COVID-19 coagulopathy has a multifaceted, chameleon spectrum of coagulopathy with platelet aberrations often playing a large role. Therefore, they recommended that patient-tailored diagnosis/characterization and treatment of COVID-19 coagulopathy should be based on a standardized algorithm employing TEG-PM. The study was published in the December 2020 issue of the journal Critical Care Explorations.

Related Links:
Memorial Regional Hospital
Haemonetics


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.